This program will include a discussion of offlabel treatment and investigational agents not approved by the Food and Drug Administration for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journ ID: 775500
Download Presentation The PPT/PDF document " Moving Evidence into Practice: Breast C..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Moving Evidence into Practice: Breast Cancer Highlights From Chicago
Slide2This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
Slide3I-SPY 2 Study
Slide4I-SPY 2 TRIAL Schema: HER2- Signatures
Slide5Pembrolizumab Graduated in All HER2- Signatures:Both HR+/HER2- and TNBC
Slide6Select Treatment-Related Adverse Events
Slide7AEs of Special Interest (Including Immune-Related Toxicities)
Slide8Primary and Secondary Adrenal Insufficiency
Slide9Conclusions
Slide10MONARCH 2 Phase 3 Trial
Slide11MONARCH 2 Results
Slide12Abemaciclib for Treatment of Brain Metastases
Slide13MONALEESA-2 Phase 3 Trial: Second Interim Analysis
Slide14PALOMA-1 Study
Slide15OlympiAD Trial
Slide16OlympiAD Trial: Results
Slide17Brightness Study
Slide18Brightness Efficacy Results
Slide19ABRAZO Phase 2 Clinical Trial: Key Eligibility Criteria
Slide20Primary Efficacy Endpoint: Talazoparib ORR by Independent Radiologist Facility
Slide21APHINITY Trial
Slide22APHINITY Results
Slide23Results of Subgroup Analysis of IDFS at 4 Years
Slide24Safety Profile
Slide25APT Trial
Slide26Updated Analysis of APT Trial
Slide27Abbreviations
Slide28Abbreviations (cont)